Use of anakinra in severe COVID-19: A case report

Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Filocamo, Giovanni, Mangioni, Davide, Tagliabue, Paola, Aliberti, Stefano, Costantino, Giorgio, Minoia, Francesca, Bandera, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211644/
https://www.ncbi.nlm.nih.gov/pubmed/32437934
http://dx.doi.org/10.1016/j.ijid.2020.05.026
Descripción
Sumario:Coronavirus disease 19 is a global healthcare emergency with a high lethality rate. Relevant inflammatory cytokine storm is associated with severity of disease, and IL1 inhibition is a cornerstone treatment for hyperinflammatory diseases. We present here the case of a patient with critical COVID-19 successfully treated with IL-1 receptor antagonist (anakinra).

Ejemplares similares